FDA 483 - Laboratorios Farmaceuticos Rovi S. A. - June 27, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Laboratorios Farmaceuticos Rovi S. A. in Madrid, Spain, revealed significant deficiencies in sterile drug manufacturing. The firm failed to adequately investigate unexplained discrepancies and out-of-specification results, did not follow procedures to prevent microbiological contamination, and used equipment not of appropriate design. Additionally, the quality control unit's responsibilities were not fully followed, particularly regarding the review of contract manufacturer data, indicating serious concerns for product quality and safety.
ID · 1ae6f9ba-c43c-471c-ac33-2f9ba5a38f6e